A Phase 3 interventional study of Calcipotriol plus hydrocortisone ointment vehicle and Tacalcitol Ointment in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.
Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.
Among the 47 studies testing calcipotriene in Psoriasis, this one is the 8th largest by enrollment, is one of 5 that started in 2008, is one of 17 in phase 3, and was the 13th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 19 · Phase 4 12
First in 2004; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 782 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 200 across the 47 interventional studies. Of the 41 that completed or were terminated, 21 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 47 have an industry lead sponsor. The 10 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
79 studies in Psoriasis by LEO Pharma: 1 open now, 2 under way, none of them phase 3. Of 77 finished, 36 (47%) have results posted.
Among the 79 studies in Psoriasis by LEO Pharma, this one is the 8th largest by enrollment of the 71 interventional ones that give a count, is one of 5 that started in 2008, is one of 20 in phase 3, and was the 9th registered.
LEO Pharma’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing calcipotriene in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among LEO Pharma’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to compare the efficacy and safety of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g with tacalcitol 4 mcg/g ointment and the ointment vehicle alone in patients with psoriasis vulgaris on the face and on the intertriginous ares
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Calcipotriol plus Hydrocortisone ointment once daily for up to 8 weeks
Drug: Calcipotriol plus hydrocortisone ointment
Tacalcitol once daily for up to 8 weeks
Drug: Tacalcitol Ointment
Calcipotriol plus Hydrocortisone ointment vehicle once daily for up to 8 weeks
Drug: Calcipotriol plus hydrocortisone ointment vehicle
Once daily application for up to 8 weeks
Once daily application for up to 8 weeks
Drug pages: Calcipotriene · Hydrocortisone
Once daily application for up to 8 weeks
Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8
Time frame: Week 8
Overall Disease Severity of the Face According to the Investigator's Assessment
Time frame: Week 4
Total Sign Score of the Face
Time frame: Week 8
Severity Scores for Redness, Thickness and Scaliness of the Face
Time frame: Week 8
Overall Disease Severity of the Intertriginous Areas According to the Investigator's Assessment
Time frame: Week 8
Total Sign Score of the Intertriginous Areas
Time frame: Week 8
Patients With Relapse During the Study and Time to Relapse
Time frame: Week 8-16
Patients With Rebound During the Study
Time frame: Week 8-16
Date of first subject visit was 5 Mar 2008. Date of last subject visit was 18 Jun 2009. Patients came from hospital outpatient clinics or private practice
| Milestone | Calcipotriol Plus Hydrocortisone Ointment | Tacalcitol Ointment | Calcipotriol Plus Hydrocortisone Ointment Vehicle |
|---|---|---|---|
| Started | 322 | 317 | 102 |
| Completed | 279 | 258 | 77 |
| Not completed | 43 | 59 | 25 |
| Participants | Calcipotriol Plus Hydrocortisone Ointment | Tacalcitol Ointment | Calcipotriol Plus Hydrocortisone Ointment Vehicle |
|---|---|---|---|
| Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8 | 183 | 147 | 37 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Calcipotriol Plus Hydrocortisone Ointment | — | 5/321 (1.6%) | 13/321 (4%) |
| Tacalcitol Ointment | — | 3/316 (0.9%) | 30/316 (9.5%) |
| Calcipotriol Plus Hydrocortisone Ointment Vehicle | — | 4/102 (3.9%) | 2/102 (2%) |
| Event | Calcipotriol Plus Hydrocortisone Ointment | Tacalcitol Ointment | Calcipotriol Plus Hydrocortisone Ointment Vehicle |
|---|---|---|---|
| Abscess limbInfections and infestations | 0/321 | 0/316 | 1/102 |
| PregnancyPregnancy, puerperium and perinatal conditions | 1/321 | 2/316 | 1/102 |
| DisorientationPsychiatric disorders | 0/321 | 0/316 | 1/102 |
| ThrombosisVascular disorders | 0/321 | 0/316 | 1/102 |
| Hip arthroplastySurgical and medical procedures | 0/321 | 1/316 | 0/102 |
| Myocardial infarctionCardiac disorders | 1/321 | 0/316 | 0/102 |
| Lower limb fractureInjury, poisoning and procedural complications | 1/321 | 0/316 | 0/102 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/321 | 0/316 | 0/102 |
| EpilepsyNervous system disorders | 1/321 | 0/316 | 0/102 |
| Event | Calcipotriol Plus Hydrocortisone Ointment | Tacalcitol Ointment | Calcipotriol Plus Hydrocortisone Ointment Vehicle |
|---|---|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 13/321 | 30/316 | 2/102 |
| Age, Continuous(years) | Calcipotriol Plus Hydrocortisone Ointment | Tacalcitol Ointment | Calcipotriol Plus Hydrocortisone Ointment Vehicle | Total |
|---|---|---|---|---|
| Mean | 48 ± 15.5 | 49 ± 15.5 | 48.8 ± 14.2 | 48.5 ± 15.3 |
| Sex: Female, Male(Participants) | Calcipotriol Plus Hydrocortisone Ointment | Tacalcitol Ointment | Calcipotriol Plus Hydrocortisone Ointment Vehicle | Total |
|---|---|---|---|---|
| Female | 126 | 136 | 41 | 303 |
| Male | 196 | 181 | 61 | 438 |
| Region of Enrollment(participants) | Calcipotriol Plus Hydrocortisone Ointment | Tacalcitol Ointment | Calcipotriol Plus Hydrocortisone Ointment Vehicle | Total |
|---|---|---|---|---|
| France | 95 | 83 | 38 | 216 |
| Canada | 131 | 129 | 37 | 297 |
| United Kingdom | 96 | 105 | 27 | 228 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Feb 2008, a primary completion of Jun 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Calcipotriene · Hydrocortisone